Sign In
Buy ITOS
$10.15
+0 (+0%)
At Close: Nov 28, 2025
iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share
10:37am, Sunday, 15'th Aug 2021
iTeos Therapeutics had a cash balance of about $26.40 per share as of June 30, 2021. iTeos Therapeutics received a non-refundable upfront payment from GlaxoSmithKline representing revenue of approxima
iTeos Therapeutics' (ITOS) CEO Michel Detheux on Q2 2021 Results - Earnings Call Transcript
02:54am, Friday, 13'th Aug 2021
iTeos Therapeutics' (ITOS) CEO Michel Detheux on Q2 2021 Results - Earnings Call Transcript
iTeos Reports Second Quarter 2021 Financial Results and Provides Business Update
07:00am, Thursday, 12'th Aug 2021
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 12, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development
iTeos Therapeutics to Present at Wedbush PacGrow Healthcare Conference 2021
07:00am, Tuesday, 03'rd Aug 2021
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development
iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021
10:03am, Thursday, 08'th Jul 2021
CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 08, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development
Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug
09:01am, Tuesday, 15'th Jun 2021
Glaxo (GSK) signs deal with iTeos Therapeutics to co-develop its investigational cancer candidate known as EOS-448. Glaxo will also study EOS-448 with its other investigational cancer therapies.
Why iTeos Therapeutics Stock Soared Today
04:55pm, Monday, 14'th Jun 2021
The biotech struck a potential $2 billion deal with a pharmaceutical giant.
Why iTeos Therapeutics Shares Are Surging Today
01:35pm, Monday, 14'th Jun 2021
iTeos Therapeutics Inc (NASDAQ:ITOS) shares are trading higher by 36.7% at $27.38 Monday afternoon after the company and GlaxoSmithKline announced an agreement to co-develop and co-commercialize EOS
ITOS Stock Price: Over 40% Increase Pre-Market Details
09:09am, Monday, 14'th Jun 2021
The stock price of iTeos Therapeutics Inc (NASDAQ: ITOS) increased by over 40% pre-market. These are the details.
iTeos Therapeutics Stock Surges On $2.1B Development Pact For EOS-448 With GSK
07:47am, Monday, 14'th Jun 2021
iTeos Therapeutics (NASDAQ: ITOS) and GlaxoSmithKline plc (NYSE: GSK) have agreed to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody. Under the terms of the collaboratio
GOSSELIES, Belgium and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics (NASD: ITOS) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement to co-develop and co-commercialise
iTeos Therapeutics' (ITOS) CEO Michel Detheux on Q1 2021 Results - Earnings Call Transcript
07:07pm, Friday, 14'th May 2021
iTeos Therapeutics' (ITOS) CEO Michel Detheux on Q1 2021 Results - Earnings Call Transcript
iTeos Reports First Quarter 2021 Financial Results and Provides Business Update
04:01pm, Thursday, 13'th May 2021
- Presented differentiated clinical and pharmacodynamic data from Phase 1/2a trial of anti-TIGIT antibody, EOS-448, at AACR 2021; expansion into combination cohorts expected mid-2021 -
CAMBRIDGE, Mass. and GOSSELIES, Belgium, April 10, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), clinical-stage biopharmaceutical company pioneering the discovery and development o
3 Biotech Stocks With Big Catalysts Around the Corner
05:56am, Saturday, 10'th Apr 2021
Upcoming events could send these stocks screaming higher or lower.
